Study #2020-0259
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
MD Anderson Study Status
Not Accepting
Treatment Agent
INCB081776, INCMGA00012
Description
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumors
Study phase:
Phase I
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-961-3045
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.